Reuters logo
Ranbaxy beats class certification bid in pay-for-delay case
August 29, 2017 / 9:54 PM / 3 months ago

Ranbaxy beats class certification bid in pay-for-delay case

A federal judge has declined to certify a class of drug wholesalers who accuse generic drugmaker Ranbaxy Laboratories of illegally accepting payments from Cephalon Inc to delay the release of a generic version of the wakefulness drug Provigil.

Monday’s ruling by U.S. District Judge Mitchell Goldberg in Philadelphia for the Sun Pharmaceutical Industries Ltd unit came after a federal appeals court ordered him to reconsider an earlier decision certifying the same class of wholesalers.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2vHFEPS

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below